Instituto Mexicano Del Seguro Social CIBIS IMSS

Xochitepec, Mexico

Instituto Mexicano Del Seguro Social CIBIS IMSS

Xochitepec, Mexico
SEARCH FILTERS
Time filter
Source Type

Romero-Cerecero O.,Instituto Mexicano del Seguro Social CIBIS IMSS | Islas-Garduno A.L.,Scholarship student | Zamilpa A.,Instituto Mexicano del Seguro Social CIBIS IMSS | Tortoriello J.,Instituto Mexicano del Seguro Social CIBIS IMSS
Phytotherapy Research | Year: 2017

Previous clinical studies have demonstrated the antifungal effectiveness of Ageratina pichinchensis extracts when topically administered to patients with dermatomycosis. The objective of this study was to evaluate the effectiveness and tolerability of a 7% standardized extract of A. pichinchensis (intravaginal) in patients with vulvovaginal candidiasis. The extract was standardized in terms of its encecalin content and administered during 6 days to patients with Candida albicans-associated vulvovaginitis. The positive control group was treated with Clotrimazole (100 mg). On day 7 of the study, a partial evaluation was carried out; it demonstrated that 94.1% of patients treated with Clotrimazole and 100% of those treated with the A. pichinchensis extract referred a decrease or absence of signs and symptoms consistent with vulvovaginal candidiasis. In the final evaluation, 2 weeks after concluding administration, 86.6% of patients in the control group and 81.2% (p = 0.65) of those treated with the A. pichinchensis extract demonstrated therapeutic success. Statistical analysis evidenced no significant differences between the two treatment groups. With the results obtained, it is possible to conclude that the standardized extract from A. pichinchensis, intravaginally administered, showed therapeutic and mycological effectiveness, as well as tolerability, in patients with vulvovaginal candidiasis, without noting statistical differences in patients treated with Clotrimazole. Copyright © 2017 John Wiley & Sons, Ltd. Copyright © 2017 John Wiley & Sons, Ltd.


Romero-Cerecero O.,Instituto Mexicano Del Seguro Social CIBIS IMSS | Zamilpa A.,Instituto Mexicano Del Seguro Social CIBIS IMSS | Tortoriello J.,Instituto Mexicano Del Seguro Social CIBIS IMSS
Planta Medica | Year: 2015

Previous works have shown that extracts obtained from Ageratina pichinchensis are capable of reducing the time needed for wounds to heal. By means of a randomized, double-blind pilot study, the objective of this work was to evaluate the effectiveness and tolerability of a phytopharmaceutical developed with a standardized extract (5 %, cream formulation) of A. pichinchensis, topically administered in patients with diabetic foot ulcer. Micronized silver sulfadiazine (1 %) was employed as a control treatment. Treatments were randomly assigned to each patient, and clinical evolution was evaluated weekly until complete healing of the wound. All patients who concluded the study achieved complete healing of their ulcers. After six weeks of treatment, patients in the experimental group exhibited a wound-healing process of 77.5 %, while that of patients in the control group was 69.8 %. A statistically significant difference was not found between groups. The average time needed for complete wound healing was 65.47±47.08 days for patients treated with the A. pichinchensis extract and 77.46±50.8 days for patients in the control group (p=0.509). There was no case in either of the groups in which adverse side effects were identified. Thus, it was concluded that the A. pichinchensis extract showed the ability to improve the healing process in patients with diabetic foot ulcer; however, no statistically significant differences were observed when compared with results obtained in patients administered the control treatment (micronized silver sulfadiazine). Some limitations of this study must be addressed, such as small sample size. This work comprises a pilot study that could be useful in a future clinical trial with a greater number of patients. © Georg Thieme Verlag KG Stuttgart New York.


Osuna L.,Instituto Mexicano del Seguro Social CIBIS IMSS | Tapia N.,Instituto Mexicano del Seguro Social CIBIS IMSS | Zamilpa A.,Instituto Mexicano del Seguro Social CIBIS IMSS | Jimenez-Ferrer E.,Instituto Mexicano del Seguro Social CIBIS IMSS | Tortoriello J.,Instituto Mexicano del Seguro Social CIBIS IMSS
Engineering in Life Sciences | Year: 2014

Galphimia glauca produces compounds denominated galphimines (galphimine-A, galphimine-B and galphimine-E). Due to their important anxiolytic activity, we initiated in vitro cultures of the species with the purpose of developing a biotechnological process for obtaining galphimines. In this work, we stimulated the biosynthesis and excretion of galphimines with two-phase batch-type cell suspension cultures of G. glauca. The effect of nutritional variation and the 2,4-dichlorophenoxy acetic acid added to Murashige & Skoog(MS) culture medium was evaluated. Later, we evaluated the effect of the stimulation with calcium and methyl jasmonate (MeJ). The greatest production of galphimine-B (3.39 × 10-5 g/L day-1) was obtained on day 40 of kinetics, and induced by a treatment containing concentrations of nitrates and phosphate that are double of those normally used in MS medium, without sucrose but with added 2,4-dichlorophenoxy acetic acid (4 mg/L). Time of galphimine-B biosynthesis diminished due to the effect of MeJ in combination with calcium, and induced the excretion (100%) of galphimine-B (6.35 × 10-5 g/L day-1) into the culture medium. Thus, the use of calcium and MeJ comprises a viable alternative to stimulate the production and excretion of galphimine-B and galphimine-A in batch-type cultures of G. glauca in modified MS medium. Once optimized, the production of the anxiolytic compounds can be scaled up to the industrial level. © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Loading Instituto Mexicano Del Seguro Social CIBIS IMSS collaborators
Loading Instituto Mexicano Del Seguro Social CIBIS IMSS collaborators